IRADIMED CORPORATION

NasdaqGM:IRMD Stock Report

Market Cap: US$685.1m

IRADIMED Valuation

Is IRMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IRMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IRMD ($51.99) is trading below our estimate of fair value ($100.33)

Significantly Below Fair Value: IRMD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IRMD?

Key metric: As IRMD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IRMD. This is calculated by dividing IRMD's market cap by their current earnings.
What is IRMD's PE Ratio?
PE Ratio35.4x
EarningsUS$18.63m
Market CapUS$685.13m

Price to Earnings Ratio vs Peers

How does IRMD's PE Ratio compare to its peers?

The above table shows the PE ratio for IRMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.5x
VREX Varex Imaging
16.4x16.2%US$558.2m
TCMD Tactile Systems Technology
24.3x29.3%US$375.1m
ZYXI Zynex
51.5x45.8%US$257.6m
INMD InMode
9.9x7.5%US$1.6b
IRMD IRADIMED
35.4x15.5%US$685.1m

Price-To-Earnings vs Peers: IRMD is expensive based on its Price-To-Earnings Ratio (35.4x) compared to the peer average (25.5x).

Price to Earnings Ratio vs Industry

How does IRMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.3xn/aUS$13.07m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
IRMD 35.4xIndustry Avg. 36.9xNo. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: IRMD is good value based on its Price-To-Earnings Ratio (35.4x) compared to the US Medical Equipment industry average (36.9x).

Price to Earnings Ratio vs Fair Ratio

What is IRMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IRMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.4x
Fair PE Ratio23.2x

Price-To-Earnings vs Fair Ratio: IRMD is expensive based on its Price-To-Earnings Ratio (35.4x) compared to the estimated Fair Price-To-Earnings Ratio (23.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$94.4b

Operates as a health benefits company in the United States.

ELV

US$400.69

7D

-5.2%

1Y

-13.4%

Centene

US$29.6b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$57.46

7D

-4.5%

1Y

-20.9%

Lantheus Holdings

US$5.6b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$76.83

7D

-12.2%

1Y

12.7%